68 results
Page 2 of 4
424B5
z1yrkbxf7wsqw34 cs
14 Mar 22
Prospectus supplement for primary offering
5:26pm
424B5
tfcvs6gpd5zys
10 Jan 22
Prospectus supplement for primary offering
8:00am
424B5
fam7dmtw6s1chmy
8 Oct 21
Prospectus supplement for primary offering
5:21pm
424B5
ao8sble84zd
7 Oct 21
Prospectus supplement for primary offering
5:24pm
8-K
nfm47 tgxz
10 Sep 21
Regulation FD Disclosure
4:31pm
424B5
e3r3cm
18 Mar 21
Prospectus supplement for primary offering
5:01pm
8-K
w57be npkgz0f
14 Jan 21
Results of Operations and Financial Condition
8:30am
8-K
EX-99.1
s5d2dvkyln
14 Jan 21
Results of Operations and Financial Condition
8:30am
8-K
ba3ghhvu
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
EX-10.3
13ysp366ifd31vm01y4
17 Aug 20
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.4
mpxk0f16bmnooomyvyk
17 Aug 20
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.2
mi3qew i61yezylvtk
17 Aug 20
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.1
jbo3kd5f3
17 Aug 20
Departure of Directors or Certain Officers
4:30pm
8-K
EX-99.1
o0sqoc7 quf
14 Nov 19
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
4:38pm